Drugs / GLB-COV2-043
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05602961 | Feb 2023 → Sep 2024 | COVID-19 | GreenLight Biosciences, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLB-COV2-043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05602961 ↗ |
| Modality | Messenger RNA (mRNA) | “an mRNA Vaccine Candidate Against SARS-CoV-2” NCT05602961 ↗ |